← Back to Analyst Consensus 
RPRX Buy
Royalty Pharma plc
Current Price —
Implied Upside —
Analysts 14
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 1 reiterations from 1 firms
Next Earnings
Nov 4, 2026 (9 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 7, 2026 | Morgan Stanley | maintain | Overweight → Overweight | — | 54% |
| Sep 8, 2026 | TD Cowen | maintain | Buy → Buy | — | 54% |
| Aug 7, 2026 | JP Morgan | maintain | Overweight → Overweight | — | 55% |
| Jul 13, 2026 | TD Cowen | maintain | Buy → Buy | — | 54% |
| May 7, 2026 | Citigroup | maintain | Buy → Buy | — | 54% |
| May 7, 2026 | JP Morgan | maintain | Overweight → Overweight | — | 55% |
| Apr 21, 2026 | UBS | maintain | Buy → Buy | — | 54% |
| Apr 10, 2026 | Morgan Stanley | maintain | Overweight → Overweight | — | 54% |
| Jan 30, 2026 | UBS | upgrade | Neutral → Buy | — | 54% |
| Jan 27, 2026 | Citigroup | maintain | Buy → Buy | $50 | 54% |
| Dec 11, 2025 | TD Cowen | maintain | Buy → Buy | $45 | 54% |
| Oct 10, 2025 | Morgan Stanley | maintain | Overweight → Overweight | $54 | 54% |
| Sep 30, 2025 | Goldman Sachs | initiate | — → Buy | $42 | 54% |
| Jul 22, 2025 | Citigroup | maintain | Buy → Buy | $42 | 54% |
| Jul 10, 2025 | Morgan Stanley | maintain | Overweight → Overweight | $54 | 54% |
| Oct 25, 2024 | Citigroup | maintain | Buy → Buy | $40 | 54% |
| Aug 14, 2024 | Goldman Sachs | maintain | Buy → Buy | $51 | 54% |
| Jul 11, 2024 | Morgan Stanley | maintain | Overweight → Overweight | $51 | 54% |
| Jun 3, 2024 | UBS | downgrade | Buy → Neutral | $28 | 54% |
| Apr 12, 2024 | B of A Securities | maintain | Buy → Buy | $38 | 53% |
| Feb 20, 2024 | JP Morgan | maintain | Overweight → Overweight | $42 | 55% |
| Feb 20, 2024 | Goldman Sachs | maintain | Buy → Buy | $50 | 54% |
| Nov 9, 2023 | Morgan Stanley | maintain | Overweight → Overweight | $57 | 54% |
| Oct 11, 2023 | Morgan Stanley | maintain | Overweight → Overweight | $54 | 54% |
| Aug 9, 2023 | Morgan Stanley | maintain | Overweight → Overweight | $53 | 54% |
| Jul 11, 2023 | Morgan Stanley | reiterate | Overweight → Overweight | $52 | 54% |
| May 10, 2023 | Morgan Stanley | maintain | — → Overweight | $52 | 54% |
| Apr 10, 2023 | Morgan Stanley | maintain | — → Overweight | $50 | 54% |
| Apr 6, 2023 | Tigress Financial | reiterate | — → Buy | $60 | 55% |
| Feb 16, 2023 | UBS | maintain | — → Buy | $48 | 54% |
| Dec 6, 2022 | Morgan Stanley | maintain | — → Overweight | $51 | 54% |
| Nov 9, 2022 | Morgan Stanley | maintain | — → Overweight | $54 | 54% |
| Oct 18, 2022 | JP Morgan | maintain | — → Overweight | $52 | 55% |
| Aug 8, 2022 | Morgan Stanley | maintain | — → Overweight | $51 | 54% |
| Jul 14, 2022 | Tigress Financial | maintain | — → Buy | $57 | 55% |
| Jun 14, 2022 | UBS | initiate | — → Buy | $47 | 54% |
| May 13, 2022 | Scotiabank | initiate | — → Outperform | $53 | 55% |
| Apr 27, 2022 | Goldman Sachs | initiate | — → Buy | $56 | 54% |
| Apr 14, 2022 | JP Morgan | upgrade | Neutral → Overweight | $50 | 55% |
| Apr 6, 2022 | Morgan Stanley | upgrade | Equal-Weight → Overweight | $48 | 54% |
| Oct 29, 2021 | Citigroup | upgrade | Neutral → Buy | $50 | 54% |
| Aug 16, 2021 | Morgan Stanley | maintain | — → Equal-Weight | $46 | 54% |
| Jul 30, 2021 | Tigress Financial | initiate | — → Buy | $50 | 55% |
| Nov 9, 2020 | UBS | upgrade | Neutral → Buy | $51 | 54% |
| Jul 13, 2020 | JP Morgan | initiate | — → Neutral | $50 | 55% |
| Jul 13, 2020 | B of A Securities | initiate | — → Buy | $55 | 53% |
| Jul 13, 2020 | Morgan Stanley | initiate | — → Equal-Weight | $51 | 54% |
| Jul 13, 2020 | Cowen & Co. | initiate | — → Outperform | $55 | — |
| Jul 13, 2020 | SunTrust Robinson Humphrey | initiate | — → Buy | $56 | — |
Price Target Trend
May 24, 2026 Oct 26, 2026
EPS Estimates
+1y —
+1q —
0y —
0q —
Cross-Platform Signals
No cross-platform signals in the last 90 days